Oct 29, 2026 —
Aspen Neuroscience has priced its initial public offering, raising about $141 million to advance its cell therapy for Parkinson’s disease. The company sold roughly 9.4 million shares at $15 each, at the low end of its range.
Aspen’s lead program is an autologous therapy that reprograms a patient’s own cells into induced pluripotent stem cells and then into the dopamine-producing neurons lost in Parkinson’s. Because it uses the patient’s own cells, it avoids immune rejection but puts manufacturing and logistics at the center of the approach.
The listing adds to a run of cell and gene therapy IPOs and will fund deeper clinical testing.
